title: Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
abstract: BACKGROUND
  Renal impairment (RI) is a common presenting complication of multiple myeloma (MM); the availability of new treatments has improved the outcomes of patients with MM; however, their impact on the survival of patients who present with RI has not been extensively studied.
  
  
  METHODS
  We analyzed the characteristics and outcomes of 1773 consecutive unselected patients who were treated for symptomatic myeloma since January 1990.
  
  
  RESULTS
  Although there was a significant increase in the proportion of patients of advanced age in the more recent periods, the frequency of RI as well as the proportion of patients who presented with severe RI (eGFR < 30 ml/min/1.73 m(2)) remained unchanged around 18%. Thus, after adjustment for age, there was a decrease in the risk of severe RI at presentation after 2000. Myeloma response rates (≥PR) to frontline therapy have substantially increased, and this was translated in a significant increase in the median survival. Specifically for patients with severe RI, the median OS has improved from 18 and 19.5 months in the 1990-1994 and 1995-1999 to 29 and 32 months for the periods 2000-2004 and after 2005 (P = 0.005). Severe RI was associated with a high risk of early death (12% versus 7% for patients with moderate RI versus 3% for patients with mild or no RI (P < 0.001), especially among older patients, and has remained unchanged over time.
  
  
  CONCLUSIONS
  There has been a major improvement in the survival of patients with severe RI in the past decade, despite the increasing numbers of patients of advanced age. However, the risk of early death remains high in patients with severe RI, especially in the elderly.
authors.affiliation: Greek Myeloma Study Group, Athens, Greece.
authors.forename: M A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: S
authors.initials: S
authors.lastname: Delimpasi
authors.forename: E
authors.initials: E
authors.lastname: Katodritou
authors.forename: A
authors.initials: A
authors.lastname: Vassou
authors.forename: M C
authors.initials: MC
authors.lastname: Kyrtsonis
authors.forename: P
authors.initials: P
authors.lastname: Repousis
authors.forename: Z
authors.initials: Z
authors.lastname: Kartasis
authors.forename: A
authors.initials: A
authors.lastname: Parcharidou
authors.forename: M
authors.initials: M
authors.lastname: Michael
authors.forename: E
authors.initials: E
authors.lastname: Michalis
authors.forename: D
authors.initials: D
authors.lastname: Gika
authors.forename: A
authors.initials: A
authors.lastname: Symeonidis
authors.forename: A
authors.initials: A
authors.lastname: Pouli
authors.forename: K
authors.initials: K
authors.lastname: Konstantopoulos
authors.forename: E
authors.initials: E
authors.lastname: Terpos
authors.forename: E
authors.initials: E
authors.lastname: Kastritis
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011719:Pyrazines / Q000008:administration & dosage; D051437:Renal Insufficiency / Q000209:etiology / Q000401:mortality* / Q000503:physiopathology; D012306:Risk; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib
keywords: bortezomib; elderly; lenalidomide; renal impairment; thalidomide